68Ga-DOTA-TATE—a source of eye lens exposure for nuclear medicine department workers

Abstract

Listen

Translate article

Introduction. Obtaining 68Ga-DOTA-TATE (a radioconjugate consisting of the somatostatin analogue tyrosine-3-octreotate (Tyr3-octreotate or TATE) labelled with the positron emission tomography tracer gallium 68Ga via the macrocyclic chelating agent dodecanetetraacetic acid (DOTA)) is a complex process and, as with any radiopharmaceutical whose basis is a short-lived radionuclide generator, it is based on a sequence of procedures beginning from the 68Ge/68Ga generator elution, labelling ligands with a radioisotope, dispensing doses of 68Ga-DOTA-TATE for patients and finally injection of the preparation to patients. The complexity of this process may contribute to an increased exposure of eye lenses of the staff who perform the above-mentioned procedures, which is especially important at a time when the dose limit on the lens of the eye is being reduced from 150 to 20 mSv yr–1. Objective. The work presents the exposure of eye lenses of the personnel of a nuclear medicine department who prepare and inject 68Ga-DOTA-TATE. Materials and methods. Radiochemists and nurses were monitored by dosimetry measurements with thermoluminescent detectors (TLDs). Results. The values of Hp(3)/A—normalised personal eye dose equivalent recorded in the group of radiochemists during the procedure of dispensing the doses of 68Ga-DOTA-TATE for patients exceeded the value of 274 μSv/GBq. Conclusions. The estimated annual Hp(3) values may exceed 20 mSv, which is particularly important due to the fact that procedures using the 68Ga radioactivity are only a small part of the daily professional activity of the staff, resulting from the performance of other procedures that require the use of other radioisotopes.